“Sepsis is a complex and fatal complication. Despite decades of research, there remains a lack of treatment,” Dr. Wang said in a Feb. 3 press statement. “The hope is that by identifying this new protein mediator to curb uncontrolled inflammation, new drugs may be developed to prevent unnecessary death in septic patients.”
Researchers looked at the ways monoclonal antibodies can work to combat a pro-inflammatory protein mediator and created a new panel of antibodies with the protein that neutralized and lowered the inflammatory response — and in their experiments, this saved mice from sepsis.
“Lacking effective therapies for sepsis other than adjunctive use of antibiotics, fluid resuscitation, and supportive care, it is still urgent to search for other late-acting pathogenic mediators that offer wider therapeutic opportunities,” researchers wrote.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
